Medtronic's Q3 Profit In Line With Expectation Despite COVID-19 Impact On Procedure Volume

Medtronic Plc's MDT Q3 FY22 sales of $7.76 billion flat year-over-year as reported and an increase of 2% on an organic basis, missing the consensus of $7.90 billion. 

• The Company's third-quarter revenue results reflect the unfavorable market impact of COVID-19 and health system labor shortages on medical device procedure volumes.
• Q3 adjusted EPS of $1.37 increased 6.2% from $1.29 a year ago, in line with the analyst consensus.
• Related: Medtronic Scores Expanded FDA Nod For Cardiac Cryoablation Catheters In Pediatric Patients With Heart Rhythm Condition.
• Sales at Medtronic's heart devices unit jumped 1% Y/Y (3% organic) to $2.74 billion. 
• Spine & neurosurgery product segment sales increased 1% (2%) to $2.14 billion.
• Diabetes revenue of $584 million decreased 7% as reported and 5% organic.
• The Medical Surgical Portfolio sales decreased 1% (+1% organic) to $2.290 billion. 
• Guidance: Medtronic expects Q4 FY21 organic revenue growth of approximately 5.5%, in line with current fourth-quarter organic revenue growth Street consensus. 
• The Q4 revenue would be negatively affected by approximately $185 million.
• The Company expects Q4 adjusted EPS of $1.56 - $1.58, versus the consensus of $1.58.
• Price Action: MDT shares are down 0.06% at $100.50 during the premarket session on the last check Tuesday.